// App-Quantinova.ai

11003 : Discordance between HER2-phenotype on circulating tumor cells and primary tumor in women with advanced breast cancer.

Researchers

Presenter

  • Amelie Schramm

Principal Investigators

  • Thomas W. P. Friedl

  • Fabienne Schochter

  • Volkmar Mueller

  • Bahriye Aktas

  • Klaus Pantel

  • Natalia Krawczyk

  • Wolfgang Janni

  • Brigitte Kathrin Rack

  • Marianna Alunni-Fabbroni

  • Peter A. Fasching

  • Florin-Andrei Taran

  • Andreas D. Hartkopf

  • Andreas Schneeweiss

Medical Centers

  • II. Medical Clinic & Institute of Tumor Biology, Campus Forschung, University Hospital Hamburg-Eppendorf, Hamburg, Germany

  • Universitatsklinikum Ulm, Ulm, Germany

  • Heidelberg University Hospital, Heidelberg, Germany

  • Department of Gynecology and Obstetrics University Ulm, Ulm, Germany

  • University of Ulm, Ulm, Germany

  • Comprehensive Cancer Center, Erlangen, Germany

  • University Hospital of Essen, Essen, Germany

  • I. Universitaetsfrauenklinik, Hebertshausen, GermanyDepartment of Gynecology and Obstetrics, Ludwig-Maximilians-University Munich, Munich, GermanyDivision of Gynecological Oncology, Dept. Obstetrics and Gynecology, Ulm University, Ulm, Germany

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Department of Gynecology and Obstetrics University Ulm, Ulm, Germany

  • University Hospital, Duesseldorf, Germany

  • Department of Gynecology and Obstetrics Heinrich-Heine-University Dusseldorf, Duesseldorf, Germany

  • Universitatsklinikum Ulm, Ulm, Germany

  • Department of Gynecology and Obstetrics, University of Tuebingen, Tuebingen, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • N/A

Outcome

  • N/A


Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A